Alivus Life Sciences [GLS] vs Marksans Pharma [MARKSANS] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Alivus Life Sciences Ltd. wins in 12 metrics, Marksans Pharma Ltd. wins in 6 metrics, with 0 ties. Alivus Life Sciences Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Alivus Life Sciences Ltd. | Marksans Pharma Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 31.45 | 23.96 | Marksans Pharma Ltd. |
| Price-to-Book Ratio | 4.87 | 3.20 | Marksans Pharma Ltd. |
| Debt-to-Equity Ratio | 0.01 | 12.24 | Alivus Life Sciences Ltd. |
| PEG Ratio | 2.05 | 2.91 | Alivus Life Sciences Ltd. |
| EV/EBITDA | 17.60 | 17.15 | Marksans Pharma Ltd. |
| Profit Margin (TTM) | 53.28% | 12.85% | Alivus Life Sciences Ltd. |
| Operating Margin (TTM) | 28.97% | 18.08% | Alivus Life Sciences Ltd. |
| EBITDA Margin (TTM) | 28.97% | 18.08% | Alivus Life Sciences Ltd. |
| Return on Equity | 20.19% | 15.29% | Alivus Life Sciences Ltd. |
| Return on Assets (TTM) | 16.52% | 11.75% | Alivus Life Sciences Ltd. |
| Free Cash Flow (TTM) | $2.85B | $337.45M | Alivus Life Sciences Ltd. |
| Dividend Yield | N/A | 0.62% | N/A |
| 1-Year Return | 1.86% | -2.65% | Alivus Life Sciences Ltd. |
| Price-to-Sales Ratio (TTM) | 5.66 | 3.07 | Marksans Pharma Ltd. |
| Enterprise Value | $120.91B | $84.41B | Alivus Life Sciences Ltd. |
| EV/Revenue Ratio | 5.53 | 3.01 | Marksans Pharma Ltd. |
| Gross Profit Margin (TTM) | 55.55% | 58.08% | Marksans Pharma Ltd. |
| Revenue per Share (TTM) | $178 | $62 | Alivus Life Sciences Ltd. |
| Earnings per Share (Diluted) | $38.38 | $7.94 | Alivus Life Sciences Ltd. |
| Beta (Stock Volatility) | N/A | 1.03 | N/A |
Alivus Life Sciences Ltd. vs Marksans Pharma Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. | 1.51% | 5.94% | 1.62% | 14.70% | 16.55% | 16.96% |
| Marksans Pharma Ltd. | -1.03% | 5.80% | 20.40% | 51.59% | 31.03% | 38.86% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. | 1.86% | 71.75% | 38.02% | 38.02% | 38.02% | 38.02% |
| Marksans Pharma Ltd. | -2.65% | 181.04% | 197.61% | 488.28% | 10,872.61% | 2,742.00% |
Performance & Financial Health Analysis: Alivus Life Sciences Ltd. vs Marksans Pharma Ltd.
| Metric | GLS | MARKSANS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹123.75B | ₹86.20B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 92,971 | 1,036,499 |
| 90 Day Avg. Volume | 72,770 | 832,265 |
| Last Close | ₹1,061.50 | ₹249.76 |
| 52 Week Range | ₹819.00 - ₹1,148.40 | ₹155.00 - ₹266.60 |
| % from 52W High | -7.57% | -6.32% |
| All-Time High | ₹1,335.10 (Sep 16, 2024) | ₹358.70 (Dec 02, 2024) |
| % from All-Time High | -20.49% | -30.37% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.27% | 0.11% |
| Quarterly Earnings Growth | 0.12% | 0.08% |
| Financial Health | ||
| Profit Margin (TTM) | 0.53% | 0.13% |
| Operating Margin (TTM) | 0.29% | 0.18% |
| Return on Equity (TTM) | 0.20% | 0.15% |
| Debt to Equity (MRQ) | 0.01 | 12.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹207.22 | ₹59.37 |
| Cash per Share (MRQ) | N/A | ₹14.74 |
| Operating Cash Flow (TTM) | ₹4.70B | ₹2.42B |
| Levered Free Cash Flow (TTM) | ₹4.71B | ₹3.81B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.62% |
| Last 12-Month Dividend | ₹0.00 | ₹1.40 |
Valuation & Enterprise Metrics Analysis: Alivus Life Sciences Ltd. vs Marksans Pharma Ltd.
| Metric | GLS (Apr 07, 2026) | MARKSANS (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 31.45 | 23.96 |
| Forward P/E | 22.31 | 17.29 |
| PEG Ratio | 2.05 | 2.91 |
| Price to Sales (TTM) | 5.66 | 3.07 |
| Price to Book (MRQ) | 4.87 | 3.20 |
| Market Capitalization | ||
| Market Capitalization | ₹123.75B | ₹86.20B |
| Enterprise Value | ₹120.91B | ₹84.41B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.53 | 3.01 |
| Enterprise to EBITDA | 17.60 | 17.15 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.03 |
| Book Value per Share (MRQ) | ₹207.22 | ₹59.37 |
Financial Statements Comparison: Alivus Life Sciences Ltd. vs Marksans Pharma Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | GLS (2024) | MARKSANS (2025) |
|---|---|---|
| Revenue/Sales | 21.85B | 26.14B |
| Cost of Goods Sold | 10.21B | 12.29B |
| COGS % of Revenue | 46.7% | 47.0% |
| Gross Profit | 11.64B | 13.85B |
| Gross Margin | 53.3% | 53.0% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 6.22B | 4.56B |
| Operating Margin | 28.5% | 17.4% |
| EBITDA | 6.87B | 6.06B |
| EBITDA Margin | 31.4% | 23.2% |
| Pre-Tax Income | 6.31B | 5.04B |
| Pre-Tax Income % of Revenue | 28.9% | 19.3% |
| Income Tax | 1.60B | 1.21B |
| Income Tax % of Revenue | 7.3% | 4.6% |
| Net Income (Profit) | 4.71B | 3.83B |
| Profit Margin | 21.6% | 14.6% |
Balance Sheet & Liquidity Metrics
| Metric | GLS (2024) | MARKSANS (2025) |
|---|---|---|
| Cash & Equivalents | 3.01B | 4.96B |
| Total Current Assets | 19.16B | 22.04B |
| Total Current Assets % of Revenue | 87.7% | 84.3% |
| Total Current Liabilities | 4.39B | 4.77B |
| Total Current Liabilities % of Revenue | 20.1% | 18.3% |
| Long-Term Debt | 147.61M | 2.63B |
| Long-Term Debt % of Revenue | 0.7% | 10.1% |
| Total Shareholders Equity | 23.32B | 24.89B |
| Retained Earnings | 12.92B | 14.22B |
| Retained Earnings % of Revenue | 59.1% | 54.4% |
| Property, Plant & Equipment | 7.95B | 185.74M |
Cash Flow Statement Comparison
| Metric | GLS (2024) | MARKSANS (2025) |
|---|---|---|
| Operating Cash Flow | 4.70B | 2.42B |
| Operating Cash Flow % of Revenue | 21.5% | 9.3% |
| Capital Expenditures | -1.29B | -1.72B |
| Free Cash Flow | 2.85B | 337.45M |
| FCF Margin | 13.0% | 1.3% |
| Debt Repayment | N/A | -60.06M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GLS | MARKSANS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 122.53M | 453.16M |
| Float Shares | N/A | 214.30M |
| % Held by Insiders | N/A | 44.06% |
| % Held by Institutions | N/A | 18.21% |
| % Held by Public | N/A | 37.73% |
Dividend Analysis & Yield Comparison: Alivus Life Sciences Ltd. vs Marksans Pharma Ltd.
| Metric | GLS | MARKSANS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.40 |
| Last 12-Month Dividend Yield | N/A | 0.62% |
| 3-Year Avg Annual Dividend | ₹18.00 | ₹0.72 |
| 3-Year Avg Dividend Yield | 3.82% | 0.40% |
| 3-Year Total Dividends | ₹54.00 | ₹2.15 |
| Ex-Dividend Date | Oct 17, 2023 | Aug 01, 2025 |